CD8A and cancer: While activatingthe innate immune system remains pivotal in theantitumoral immune response, previous clinical trials underscore thenecessity for a multifaceted strategy to successfully eradicate GBM.In this respect, MHC class I emerges as a key player, as this moleculefacilitates the crucial identification of cancer cells by CD8+ cytotoxicT cells.